News

insideBIGDATA || Big Data in Life Sciences – Why ‘doing things the old way’ is the Biggest Barrier to Progress

Zachary Pitluk, Ph.D., Vice President of Life Sciences and Healthcare at Paradigm4, highlights how real insight comes, not from data collection, but from intelligent data curation, computation, and application.

whitepages icon x

Drug Discovery World | Are scalable data science platforms the way forward?

Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.

whitepages icon x

Clinical Laboratory | Paradigm4 unveils analytical development data management tool to unlock Allotrope data format (ADF) ‘treasure trove’

Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…

whitepages icon x

Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified